Bridgette Collins-Burow, MD, PhD, School of Medicine
Dr. Collins-Burow’s research program combines investigator initiated proof-of principle clinical trials with solid basic-translational bench research. Dr. Collins-Burow’s research focuses on the role of novel experimental agents and epigenetic therapy in the regulation of microRNA expression in breast cancer with specific interest in triple-negative or basal phenotype breast cancer.